Jena Diwan

发表

Scheme 3, General synthetic strategy for analogs of ML261

Jiwen Zou, Santhi Ganji, Ian Pass, 2014 .

Table 3, Probe and Analog Submissions to MLSMR (Evotec) for P. falciparum G-6PDH antagonists

Stefan Vasile, Eigo Suyama, Michael Vicchiarelli, 2013 .

Figure 4, Screening and Hit advancement flowchart

Tudor I. Oprea, Bruce S. Edwards, Larry A. Sklar, 2013 .

Figure A6E, LCMS purity data at 214 nm for ML291 2nd batch –submitted to the MLSMR (SID 134228465, CID 52940465); LCMS retention time: 3.125 min; purity at 214 nm = 97.5%

Stefan Vasile, Eigo Suyama, Michael Vicchiarelli, 2013 .

Figure 9, Structure of confirmed most attractive screening hits

Jiwen Zou, Santhi Ganji, Ian Pass, 2014 .

Figure 7, Hit triage for Lipid Droplets

Jiwen Zou, Santhi Ganji, Ian Pass, 2014 .

Scheme 1, Synthesis of ML307, conditions

Santhi Ganji, Ian Pass, Robert Ardecky, 2014 .

Table 4, Probe and Analog Submissions to MLSMR (BioFocus DPI) for UBC13 Inhibitors

Santhi Ganji, Ian Pass, Robert Ardecky, 2013 .

Figure A6F, HRMS data for ML291 2nd batch –submitted to the MLSMR (SID 134228465, CID 52940465); HRMS m/z calculated for C16H17ClN3O6S [M + H+]: 414.0521, found 414.0522

Stefan Vasile, Eigo Suyama, Anthony B. Pinkerton, 2013 .

Table 3, CID 56639556 [ML307] MLS-0471611

Santhi Ganji, Ian Pass, Robert Ardecky, 2014 .

Scheme 1, Synthesis of ML304

Stefan Vasile, Eigo Suyama, Michael Vicchiarelli, 2013 .

Scheme 1, Synthesis of ML261, conditions

Jiwen Zou, Santhi Ganji, Ian Pass, 2013 .

Scheme 1, Synthesis of ML260

Jiwen Zou, Santhi Ganji, Ian Pass, 2013 .

Figure 10, SAR strategy for Scaffold I

Jiwen Zou, Santhi Ganji, Ian Pass, 2014 .

[Table], EXPERIMENTAL RESULTS FOR SID 123083137 ON OTHER TARGETS

Stefan Vasile, Eigo Suyama, Michael Vicchiarelli, 2013 .

Figure 5, Screening results and Hit validation

John C. Reed, Santhi Ganji, Ian Pass, 2011 .

Table 5, Potencies of key screening hit scaffolds

Jiwen Zou, Santhi Ganji, Ian Pass, 2014 .

Table 3, Probe and Analog Submissions to MLSMR (BioFocus DPI) for APJ Antagonists

Stefan Vasile, Eigo Suyama, Michael Vicchiarelli, 2013 .

Scheme 1, Synthesis of ML276

Stefan Vasile, Eigo Suyama, Michael Vicchiarelli, 2013 .

Scheme 2, Synthesis of ML262, conditions

Jiwen Zou, Santhi Ganji, Ian Pass, 2014 .

Figure A6C, LCMS purity data at 214 nm for ML291 1st batch (SID 123083137, CID 52940465); LCMS retention time: 3.074 min; purity at 214 nm = 95.4%

Stefan Vasile, Eigo Suyama, Michael Vicchiarelli, 2013 .

Figure 3, Flowchart Summary of Screening Results

Stefan Vasile, Eigo Suyama, Ying Su, 2011 .

Selective Bcl-2 Inhibitor Probes

Tudor I. Oprea, Bruce S. Edwards, Larry A. Sklar, 2013 .

Discovery of a Plasmodium falciparum glucose-6-phosphate dehydrogenase 6-phosphogluconolactonase inhibitor (R,Z)-N-((1-ethylpyrrolidin-2-yl)methyl)-2-(2-fluorobenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxamide (ML276) that reduces parasite growth in vitro.

Stefan Vasile, Eigo Suyama, Michael Vicchiarelli, 2012, Journal of medicinal chemistry.